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Summary
Background Diabetic foot ulcers (DFUs) are a devastating complication of diabetes.
Objectives To identify genetic contributors to the development of DFUs in the
presence of peripheral neuropathy in a Scottish cohort with diabetes using a gen-
ome-wide association study.
Methods A genome-wide association approach was applied. A case was defined as
a person with diabetes (type 1 or type 2) who had ever had a foot ulcer (current
or previous) in at least one foot, as well as a positive monofilament test result
(i.e. evidence of peripheral neuropathy) recorded in their longitudinal e-health
records. A control was defined as an individual with diabetes (type 1 or type 2)
who has never been recorded as having a foot ulcer in either foot but who had a
positive monofilament test result recorded in either foot in their longitudinal e-
health records.
Results There were 699 DFU cases and 2695 controls in the Genetics of Diabetes
Audit and Research in Tayside Scotland (GoDARTS) dataset. The single-nucleotide
polymorphism rs80028505 (Chr6p2131) in MAPK14 reached genome-wide sig-
nificance with a lowest P-value of 245 9 108. The narrow-sense heritability of
this phenotype is 006.
Conclusions We suggest that MAPK14 is associated with DFUs.
What’s already known about this topic?
• Around 25% of people with diabetes will develop foot ulceration in their lifetime.
• Diabetic foot ulcers (DFUs) account for 85% of all lower-limb amputations in the
U.K.
• There are multiple risk factors for DFUs, the strongest initiating factor being
peripheral sensory neuropathy.
• The genetics of DFUs are poorly understood.
What does this study add?
• This genome-wide association study suggests that a skin-related gene, MAPK14, is
associated with DFUs in individuals with evidence of neuropathy.
• The narrow-sense heritability of this disorder, in individuals with evidence of neu-
ropathy, is 006.
What is the translational message?
• Genetic variants in MAPK14 are strongly linked with DFUs.
• Further study is needed to confirm the gene’s role, followed by clinical trials that
should bring significant benefits to patients with DFUs.
© 2017 The Authors. British Journal of Dermatology
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Diabetic foot ulcers (DFUs) are a major and devastating compli-
cation of diabetes. According to the National Institute for Health
and Care Excellence guideline, a DFU is defined as a localized
injury to the skin and/or underlying tissue, below the ankle, in a
person with diabetes.1 It has been reported that around 25% of
people with diabetes will develop DFUs at some stage in their
lifetime.2 Although the majority of DFUs (60%–80%) will heal
without intervention or after treatment, 10%–15% of them will
remain active and 5%–24% of all patients with DFUs will eventu-
ally undergo a lower-limb amputation.3 DFUs account for 85%
of all lower-limb amputations and, in the U.K., 50% of bed
occupancy in patients with diabetes is because of diabetes-related
foot problems.4,5 DFUs have a significant impact on the quality
of life of patients, especially those with amputations. These indi-
viduals normally have increased disability, high morbidity and
higher mortality.6 In addition, the cost of treating DFUs is huge.
It is estimated that £650 million is spent on foot ulcers or ampu-
tations each year by the National Health Service (NHS) in the
U.K.1 This is equivalent to £1 in every £150 of all NHS costs.
Epidemiological studies have suggested multiple risk factors
for DFUs: diabetic neuropathy, peripheral vascular disease,
biomechanical factors, previous foot ulceration, poor glycaemic
control, longer duration of diabetes, smoking, ethnicity,
retinopathy, nephropathy, insulin use, poor vision, age and male
sex.4 Among these, diabetic neuropathy has been indicated to be
the strongest initiating factor for DFUs. A study has shown that
63% of DFUs were as a result of peripheral sensory neuropathy.7
This is followed by peripheral vascular disease, which, although
not suggested as a cause of ulceration alone, is usually found in
combination with diabetic neuropathy and other factors.8 Fur-
ther research on epidemiological risk factors can provide great
value in terms of disease prevention and treatment.
At the moment, the role of genetics in DFUs is not clearly
understood. It is assumed that DFUs are a common complex dis-
order determined by both genetic and environmental factors. A
previous gene study has suggested that rs699947 in VEGF is asso-
ciated with DFUs.2 There is increasing evidence that epigenetic
changes (i.e. molecular modification to genes) can have an
impact on the development of DFUs by affecting the healing
ability of tissues.9 So far, there have not been any linkage studies
that have reported genetic loci of DFUs. In addition, no genome-
wide association studies (GWASs) have been published so far on
DFUs. A GWAS is a hypothesis-free genetic association study
used to identify genes for complex disorders based on phenotype
information and genetic information of a population or a
cohort.10 The purpose of this study was to use a GWAS approach
to identify genetic variants for developing DFUs in the presence
of peripheral neuropathy, based on phenotype information and
genetic information from a Scottish cohort with diabetes.
Patients and methods
Participants
The Genetics of Diabetes Audit and Research in Tayside Scot-
land (GoDARTS) project was established in 2005 to identify
genetic risk factors for diabetes and its complications. Partici-
pants with and without diabetes are all required to complete a
lifestyle questionnaire, a baseline clinical examination and pro-
vide biological samples (blood and urine). All participants
provided broad informed consent for their health information
from the NHS and biological samples to be anonymously
linked to the study for future scientific research. The linked
health information includes their personal health status, their
general practice clinic visits, outpatient appointments, pre-
scribing history and hospital admissions. In addition, partici-
pants’ personal information is anonymously linked with the
Scottish Care Information-Diabetes Collaboration (SCI-DC)
database, which is an electronic health (e-health) record sys-
tem specifically designed to provide clinical information, to
support diabetic screening services and to provide data for
national and local audit programmes. Further information
about the GoDARTS project and SCI-DC database can be found
in the public domain (http://diabetesgenetics.dundee.ac.uk/
and http://www.sci-diabetes.scot.nhs.uk/). The research fol-
lowed the tenets of the Declaration of Helsinki. The Tayside
Committee on Medical Research Ethics (REC reference 053/
04) granted ethical approval for the study. So far, 9439
patients with diabetes have been recruited by the GoDARTS
project and 7424 of them have been genotyped using DNA
chips. All participants’ health information was anonymously
linked with their NHS and SCI-DC database records from June
1996 until June 2014.
Definitions of cases and controls
A case of DFU in this study was defined as a person with dia-
betes [type 1 diabetes (T1D) or type 2 diabetes (T2D)] who
had ever been recorded in the linked e-health records as hav-
ing a foot ulcer (current or previous) in at least one foot, as
well as a positive monofilament test result recorded in the lon-
gitudinal e-health records. A control in this study was defined
as a person with diabetes (T1D or T2D) who had never been
recorded as having a foot ulcer in either foot in the linked e-
health records but who had a positive monofilament test result
recorded in either foot in their longitudinal e-health records.
The monofilament test is a neurological test for patients
with diabetes to check their peripheral sensation.11 During the
test, a monofilament is pressed at 10 sites on both feet (five
sites each) with approximately 10 g pressure for a short time
(2 s). Absence of sensation in at least two out of five sites in
one foot is a positive test, suggesting peripheral neuropathy.
Genotyping and quality control
Two sets of DNA chips were applied in the GoDARTS project
to genotype participants with diabetes. The Affymetrix SNP60
chips (used for 3884 participants; Affymetrix, Santa Clara, CA,
U.S.A.) were sponsored by the Wellcome Trust Case Control
Consortium 2 (WTCCC2) project and the Illumina OmniEx-
press chips (used in 3540 participants; Illumina, San Diego,
CA, U.S.A.) were funded by the SUrrogate markers for Micro-
© 2017 The Authors. British Journal of Dermatology
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and Macro-vascular hard endpoints for Innovative diabetes
Tools (SUMMIT) project.12,13 Both projects (WTCCC2 and
SUMMIT) used standard genotyping quality-control proto-
cols.12,13
Statistical analysis
Software SHAPEIT (https://mathgen.stats.ox.ac.uk/genetic
s_software/shapeit/shapeit.html) and IMPUTE2 (http://math
gen.stats.ox.ac.uk/impute/impute_v2.html) were applied to
impute nondirectly genotyped single-nucleotide polymor-
phisms (SNPs) using reference files from the 1000 genome
phase I datasets.14,15 Badly imputed SNPs were removed based
on a cut-off value (r2 < 03) suggested by IMPUTE2.
Standard quality-control steps were frequently applied
during data manipulation stages using PLINK (https://www.
cog-genomics.org/plink2), such as removal of individuals
with > 5% missing genotype data, SNPs with missing geno-
type of > 5%, SNPs with < 1% minor allele frequency and
SNPs that failed Hardy–Weinberg tests (P < 0000001).16
SNPs on X, Y chromosomes and mitochondria were not rou-
tinely included. The multidimensional scaling (MDS) analysis
integrated in PLINK was used to detect population stratifica-
tion in the cohort. A lambda value (indicating the level of
stratification and generated by MDS) should be very close to
1, suggesting minimum ancestry mixture. If two samples in
the cohort have a pi-hat > 0125 (indicating relatedness), then
one of them was removed randomly from further association
analysis. Logistic regression tests integrated in PLINK were
used to generate association P-values, adjusting for covariates
including age, sex, body mass index (BMI), cholesterol,
triglycerides, high-density lipoprotein (HDL), low-density
lipoprotein (LDL), haemoglobin A1c (HbA1c) and duration of
diabetes. P-values less than 5 9 108 were considered to be
genome-wide significant variants. The linkage disequilibrium
among the top SNPs was also calculated by PLINK.
In this study we also used multiple related GWAS software
for different purposes such as SNPnexus (Barts Cancer Insti-
tute, Queen Mary University of London, London, U.K.) for
SNP functional annotation, HaploView (Broad Institute of MIT
and Harvard, Cambridge, MA, U.S.A.) for generating Manhat-
tan plots, LocusZOOM (Department of Biostatistics, Center for
Statistical Genetics, University of Michigan, Ann Abor, MI,
U.S.A.) for regional visualization and SNPEVG (University of
Minnesota, St Paul, MN, U.S.A.) for a corresponding Q–Q plot
to evaluate differences between cases and controls caused by
potential confounders (e.g. different genotyping laboratories
or different DNA extraction methods).17–20 SPSS 22 software
(IBM, Armonk, NY, U.S.A.) was used to compare the means
of all covariates (except sex) between cases and controls
through independent sample t-tests. Sex difference was com-
pared using the v2-test. The whole workflow is shown in Fig-
ure 1. We also calculated narrow-sense heritability (or chip
heritability, estimation of the phenotypic variance explained
by the SNPs) based on common SNPs in both chips using
GCTA software (http://cnsgenomics.com/software/gcta/
#Overview).21
Results
We identified 914 individuals with positive foot ulcer records
and 6460 individuals without foot ulcer records from 7424
patients with diabetes with genetic information from the GoD-
ARTS project (50 samples lacked solid phenotyping informa-
tion). After applying monofilament test results, only 764 DFU
cases and 3174 controls with positive monofilament test results
were suitable for further analysis based on the definitions used
in this study. After removing related individuals (n = 543) and
population outliers (n = 1), we were left with a cleaned study
population of 699 DFU cases (463 men, 236 women; 662 with
T2D and 37 with T1D) and 2695 diabetic control individuals
(1453 men, 1242 women; 2584 with T2D and 111 with T1D).
Fig 1. Workflow of the genome-wide
association study on diabetic foot ulcers
(DFUs) in Genetics of Diabetes Audit and
Research in Tayside Scotland (GoDARTS).
WTCCC2, Wellcome Trust Case Control
Consortium 2; SUMMIT, SUrrogate markers
for Micro- and Macro-vascular hard endpoints
for Innovative diabetes Tools.
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The prevalence of DFUs in our case–control population was
206% [699/(699 + 2695)]. The means of sex, age, BMI,
cholesterol, triglycerides, HDL, LDL, HbA1c, duration of dia-
betes were compared between the cases and controls. There
were statistically significant differences in sex, LDL, HbA1c and
duration of diabetes between cases and controls, whereas there
was no significant difference in age, triglycerides, BMI, choles-
terol and HDL (Table 1).
Overall, 6 706 850 genotyped and imputed SNPs were
available for association analysis after standard quality-control
steps of genotyping and imputation. No further adjustment
based on population stratification was applied since the
lambda value was 1007, indicating a homogeneous popula-
tion. Logistic regression tests integrated in PLINK were then
performed, adjusting for sex, age, BMI, cholesterol, triglyc-
erides, HDL, LDL, HbA1c and duration of diabetes. We identi-
fied that the SNP rs80028505 in MAPK14 reached genome-
wide significance with a lowest P-value of 245 9 108 and
an odds ratio of 171 (95% confidence interval 141–206)
(Fig. 2, Table 2). A cluster of SNPs in MAPK14 also showed
GWAS significant P-values (P < 5 9 108). The regional plot
of the MAPK14 region is shown in Figure 3. We calculated the
linkage disequilibrium among these SNPs (top 10 SNPs with
lowest P-values) using our dataset and they are all highly cor-
related (r2 > 08) (Fig. S1; see Supporting Information). The
Q-Q plot of the association results is shown in the Figure S2
(see Supporting Information). The narrow-sense heritability of
DFUs (with neuropathy evidence) is 006, after adjusting with
all covariates. See Table S1 (see Supporting Information) for
the results of the GWAS using only individuals with T2D, to
remove the influence from the individuals with T1D.
Discussion
In Scotland, patients with diabetes are invited to attend an
annual free foot screening and to have their feet checked by
podiatrists.22 The screening aims to identify diabetic foot
complications at an early stage to prevent or delay serious
consequences such as lower-limb amputation. During the
screening, podiatrists not only record the clinical conditions
of foot ulcers, if any (including area, size and depth), but also
clinical characteristics that might be linked with DFUs, such as
the presence or absence of foot pulses, nerve sensation and
vibration functions, previous ulceration history, significant
Table 1 Clinical characteristics of diabetic foot ulcer cases and
controls
Covariates Cases Controls P-values
Sex (male : female),
n
463 : 236 1453 : 1242 < 0001
Age (years) 6873  906 6848  920 052
Body mass index
(kg m2)
3122  515 3135  541 054
Cholesterol
(mmol L1)
431  082 437  084 006
Triglycerides
(mmol L1)
229  133 219  126 009
High-density
lipoprotein
(mmol L1)
135  033 136  034 037
Low-density
lipoprotein
(mmol L1)
200  060 207  063 001
Haemoglobin A1c
(mmol L1)
788  150 754  126 < 0001
Duration of diabetes
(years)
2131  900 1810  812 < 0001
Values are mean  SD, unless otherwise stated. A v2-test was
used to test the difference in sex frequency between cases and
controls and an independent t-test was used for other covariates.
Results in bold are significant.
Fig 2. The Manhattan plot of the genome-wide association study on diabetic foot ulcers (699 cases and 2695 controls). Single-nucleotide
polymorphisms with P-values > 001 were not included. Chr, chromosome.
© 2017 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017)
4 Genome-wide association study and diabetic foot ulcers, W. Meng et al.
structural foot deformity, presence of callus, amputation his-
tory and self-care ability. However, in the current version
(June 2014) of e-health records provided by SCI-DC to
researchers, the detailed descriptions of ulcers such as area,
size and depth are not available. DFUs are categorized as cur-
rent ulcers (left leg and right leg) and previous ulcers (left leg
and right leg) in a longitudinal manner based on examination
dates. This is the background to the DFU case definition used
in this study.
To achieve a more homogeneous case and control defini-
tion, we further adapted positive monofilament test results
(evidence of neuropathy) into the sample selection. There
were 150 patients with DFUs (164% of 914 individuals) who
did not have positive monofilament test results but had a posi-
tive foot ulcer record (current or previous). This may suggest
that the underlying genetic mechanisms of DFUs in these
patients might not be the same as for other patients with
DFUs (n = 764). This stringent definition reduced case num-
bers and the study power but generated a more homogeneous
case population. A similar approach has been successfully
applied when defining diabetic neuropathic pain, which is
another complication of diabetes (a case should not only have
pain evidence provided by prescription records, but also have
neuropathy evidence provided by positive monofilament
tests).23
In terms of controls, 3286 individuals with diabetes but
who were foot ulcer-free (509% of 6460 individuals) had
negative monofilament results and 3174 individuals had posi-
tive monofilament results. Despite the control definition used
in the study, we also tried to use the group of 3286 samples
as controls, but no SNPs achieved GWAS significance in this
study design (Fig. S3; see Supporting Information). This fur-
ther illustrated the importance of defining a correct homoge-
neous control population. After removing related samples and
Table 2 The top 10 single-nucleotide polymorphisms (SNPs) of the genome-wide association study on the diabetic foot ulcers (cases n = 699 vs.
controls n = 2695)
SNP ID
Chromosome
position (hg19) Gene
Minor
allele
Minor allele
frequency in
cases : controls, %
P-value
(no adjustment) P-value
Odds ratio 
standard error
Imputed or
genotyped by
rs80028505 6:35998388 MAPK14 T 1402 : 899 284 9 108 245 9 108 171  010 Imputed
rs16883819 6:35997768 MAPK14 T 1397 : 897 292 9 108 282 9 108 170  010 Imputed
rs112201657 6:36019076 MAPK14 C 1425 : 920 349 9 108 291 9 108 170  010 Imputed
rs3761980a,b 6:35993906 MAPK14 C 1388 : 894 401 9 108 357 9 108 169  009 Both chips
rs6932598 6:35999080 MAPK14 A 1388 : 894 423 9 108 376 9 108 169  009 Imputed
rs60481532b 6:35994942 MAPK14 T 1390 : 897 443 9 108 401 9 108 169  009 Imputed
rs58390233 6:36005100 MAPK14 A 1388 : 896 472 9 108 420 9 108 169  009 Imputed
rs2237096 6:36008002 MAPK14 A 1388: 896 472 9 108 420 9 108 169  009 Imputed
rs56715462 6:36011649 MAPK14 G 1388 : 896 457 9 108 443 9 108 169  009 Imputed
rs61763101 6:35996413 MAPK14 T 1388 : 897 485 9 108 453 9 108 169  009 Imputed
ars3761980 is also located in the solute carrier family 26 member 8 (SLC26A8) gene, which has no evidence relating it to skin. brs3761980
and rs60481532 are located in the 5-upstream region of the MAPK14 gene whereas other SNPs are located in the intronic regions of the
gene.
Fig 3. The regional plot of the MAPK14 region
in chromosome 6.
© 2017 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017)
Genome-wide association study and diabetic foot ulcers, W. Meng et al. 5
population stratification outliers, our current GWAS answered
one question: when cases and controls are likely to have dia-
betic neuropathy, which SNPs (or genetic components) con-
tribute to foot ulceration in a diabetic population?
The prevalence of DFUs (current and/or previous DFUs) in
our cohort was 206%. This is higher than the generally
reported DFU prevalence of 5%–7% in white people.24 This is
mainly because we adapted monofilament results into the case
and control definitions; in particular, we removed a large
number of individuals (n = 3286) from the controls as a
result of lack of evidence of neuropathy. This step is necessary
for a genetic study, although it is not normally required to
estimate disease prevalence in a general epidemiological study.
Furthermore, we also used previous foot ulceration history as
part of the case definition to increase the number of cases.
We have identified the SNP rs80028505, which achieved
GWAS significance (P = 245 9 108, odds ratio 171). This
SNP was supported by a cluster of nearby SNPs that also
showed significant GWAS P-values. The SNP cluster was in
MAPK14, which is a protein-coding gene located on chromo-
some 6. This gene is widely expressed in multiple organs,
including skin and soft tissues.25 The mitogen-activated pro-
tein kinase (MAPK)14 protein, an enzyme also called p38-a,
is one of the four p38 MAPKs that play an essential role in the
cascade of cellular responses evoked by extracellular stimuli
such as proinflammatory cytokines or physical stress leading
to direct activation of transcription factors.26 Evidence from a
diabetic mouse model has suggested that p38 MAPK was
phosphorylated in wounded skin and using a p38 MAPK inhi-
bitor, the level of phosphorylation was significantly reduced
and wound healing was accelerated. This was evidenced by
reduced wound width, accelerated re-epithelialization,
increased granulation and reduced inflammatory cell infiltra-
tion into the wound.27
However, the effect of the MAPK pathway on wound healing
is controversial in some studies. For example, activation of the
MAPK pathway has been suggested to promote cell collective
migration, a biological process involved in tissue formation and
repair.28 By applying a MAPK inhibitor to a diabetic rat wound
model, the rate of wound healing was reported to be reduced
by 20%.29 It was also reported that MAPK inhibitors can reverse
cutaneous wound-healing effects in a nondiabetic mouse
wounding model.30 In fact, both acute and chronic wound
healing abilities are impaired in diabetes and the MAPK path-
way has been confirmed to be activated.31–33 The MAPK path-
way is also involved in other types of ulcers, such as venous
ulcer, gastric ulcer and corneal ulcer.34–37 Most SNPs in MAPK14
affect MAPK14 expression (P = 107) according to the Geno-
type-Tissue Expression (GTEx, Broad Institute of MIT and Har-
vard, Cambridge, MA, U.S.A.) portal, particularly in skin.38
There was a statistical difference in the sexes between cases
and controls, indicating sex is a risk factor for DFUs. This is
consistent with other studies suggesting that men are more
likely to have DFUs.39
We have moderate power for this GWAS study. Calculated
by CaTS, we have 80% power based on 699 cases and 2695
controls, assuming a minor disease allele frequency of 025, a
genotypic relative risk of 140, a prevalence of DFUs in the
diabetic population of 20% and a significance level of
5 9 108.40 The narrow-sense heritability of this phenotype
was 006; this heritability excludes effects of gene–gene inter-
actions and gene–environment interactions, for example.
When defining cases and controls in the study, we only
considered neuropathy as evidenced by a positive monofila-
ment test, since it is the strongest risk factor.7 We did not
consider characteristics such as the status of foot pulses, which
indicates the existence of peripheral vascular disease. This
greatly decreased the complexity of defining samples and sta-
tistical analysis. We also included GWAS results using individ-
uals with T2D only and here the P-values of the top SNPs
increased slightly. This was probably as a result of the reduced
samples size. The reported SNP (rs699947) in VEGF was not
associated with DFUs in our dataset (P = 053).2
In conclusion, we propose that MAPK14 is associated with
DFUs in a Scottish cohort with diabetes using a GWAS
approach. Replication studies and functional studies of this
gene will help to confirm its role in DFUs and are needed to
provide insights that will facilitate the treatment of DFUs.
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